.png)
Recently, Teva Pharmaceuticals, a global drug manufacturer, agreed to a $450 million settlement with the U.S. government. The case revolved around illegal kickbacks and copay manipulation schemes designed to boost sales of their drugs at the expense of patients and Medicare. The scale of this scandal is staggering. In 2022 alone, Medicare spent an average of $6,808 per patient on the drug Copaxone, one of Teva's flagship multiple sclerosis medications, costing over $450 million that year for just this drug.
The Kickback Scheme
Teva’s kickback scheme worked through charitable foundations that were supposed to assist patients in affording their high-cost medications. Instead, these foundations were used as a way to ensure Medicare patients stayed on Teva's Copaxone despite the availability of cheaper alternatives. Teva funneled money into these foundations, who in turn paid for patients' copays, creating an illusion of affordability while continuing to burden Medicare with exorbitant drug costs.
Teva's manipulation of the system isn't an isolated case. It's part of a broader, troubling pattern where pharmaceutical companies use charitable foundations and patient assistance programs to maintain inflated drug prices. While the companies appear to be offering a helping hand, they're really using these programs to keep patients on high-priced medications, all while raking in profits from government programs like Medicare.
Disparity in Punishment
While corporations like Teva are caught and fined for these illegal schemes, the penalties they face pale in comparison to the damage inflicted. $450 million may sound like a hefty sum, but it’s a small fraction of Teva’s profits. For comparison, Teva earned $14.9 billion in revenue in 2022. When companies like Teva face fines, they often treat them as a cost of doing business—hardly a deterrent from future wrongdoing.
What’s more disturbing is the disparity in punishment between corporations and individuals involved in similar schemes. Take the case of Richard Parker, a pharmaceutical sales representative who was sentenced to 66 months in prison for engaging in a smaller-scale kickback scheme. Or consider Dr. Farid Fata, who was sentenced to 45 years in prison for prescribing unnecessary chemotherapy treatments to profit from Medicare reimbursements.
In contrast, Teva’s executives, who orchestrated a scheme that cost taxpayers hundreds of millions, have largely walked away unscathed. There’s a clear imbalance in how justice is meted out, with individual actors often facing harsher consequences than the corporations that mastermind and profit from these illegal practices.
Legal Kickbacks: Rebates and Formulary Inclusion
What’s even more shocking is the fact that certain forms of kickbacks have been legalized when it comes to insurance companies. Under current laws, rebates from drug manufacturers to insurance companies and pharmacy benefit managers (PBMs) are considered legal. These rebates often determine whether a drug gets included on an insurer’s formulary—the list of drugs they cover.
This system allows for a hidden form of kickbacks that ultimately drives up drug prices. Drug manufacturers offer rebates to secure favorable placement on formularies, ensuring that their drugs are prescribed over cheaper alternatives. But these rebates rarely benefit patients directly. Instead, they often lead to higher premiums or out-of-pocket costs, all while allowing drug prices to remain artificially inflated.
In essence, what Teva did with illegal copay assistance mirrors the legal but equally damaging practice of rebate-driven formulary placement. The only difference is that one is sanctioned by law, and the other isn’t.
Conclusion
Teva’s $450 million settlement is a reminder of the systemic issues plaguing the pharmaceutical industry. While the fines might seem large, they are little more than a slap on the wrist for companies that continue to profit at the expense of patients and taxpayers. The stark disparity between corporate punishment and individual sentencing only highlights the need for more equitable justice.
Moreover, the legal framework that allows insurance companies to benefit from rebates shows that kickbacks aren’t just a problem of the past—they’ve been institutionalized. Until we address these practices, the cycle of manipulation and inflated drug prices will continue, leaving patients and programs like Medicare to foot the bill.
If we truly want to reduce healthcare costs, we need to address the root causes, not just slap fines on bad actors after the fact. True reform will come when we stop legalizing corporate kickbacks under the guise of rebates and start prioritizing affordable healthcare for everyone.
As always, the hidden nature of our healthcare system contributes to the high prices, manipulation and fraud. That's why we use the cost plus model at Forest Park Pharmacy. Look at the price checker and see if we can save you money. For an even greater impact, talk to your employer about switching away from the PBMs who gouge you for premiums and move to us for a fundamentally better system.
Comments